## Supplementary material

### Table S1  The schedule of modified R-CODOX-M/IVAC regimens

| Drug               | Dosage     | Method | Time         |
|--------------------|------------|--------|--------------|
| **CODOX-M**        |            |        |              |
| Cyclophosphamide   | 500 mg/m²  | IV     | Day 1, 2     |
| Vincristine        | 1.5 mg/m² (maximum dose of 2 mg) | IV | Day 1 |
| Doxorubicin        | 50 mg/m²   | IV     | Day 1        |
| Methotrexate       | 2,000 mg/m²| IV     | Day 3        |
|                    |            |        |              |
| Methotrexate       | 15 mg      | IT     | Day 1        |
| Cytarabine         | 30 mg      | IT     | Day 1        |
| **IVAC**           |            |        |              |
| Ifosfamide         | 1,500 mg/m²| IV     | Day 1–3      |
| Mesna              | 200 mg/m²  | IV     | Q4H, day 1–3 from the start of ifosfamide |
| Etoposide          | 100 mg/m²  | IV     | Day 1–3      |
| Cytarabine         | 2,000 mg/m²| IV     | Q12H, day 2  |
| Methotrexate       | 15 mg      | IT     | Day 1        |
| Cytarabine         | 30 mg      | IT     | Day 1        |
| **Biological agents** |          |        |              |
| Rituximab          | 375 mg/m²  | IV     | Day 1        |
| G-CSF              | 5 µg/kg/day| SC     | 24 h after chemotherapy completion |

IV, indicates intravenous; IT, intrathecal; SC, subcutaneous; G-CSF, granulocyte colony-stimulating factor. All cycles were repeated at 21-day intervals.